論文

国際誌
2021年9月13日

Development and Evaluation of Quantitative Immunoglobulin G Enzyme-Linked Immunosorbent Assay for the Diagnosis of Coronavirus Disease 2019 Using Truncated Recombinant Nucleocapsid Protein as Assay Antigen.

International journal of environmental research and public health
  • Pierre Nsele Mutantu
  • Mya Myat Ngwe Tun
  • Takeshi Nabeshima
  • Fuxun Yu
  • Patrick Kakoni Mukadi
  • Takeshi Tanaka
  • Masato Tashiro
  • Ayumi Fujita
  • Nobuhiro Kanie
  • Ryosaku Oshiro
  • Takahiro Takazono
  • Yoshifumi Imamura
  • Tatsuro Hirayama
  • Meng Ling Moi
  • Shingo Inoue
  • Koichi Izumikawa
  • Jiro Yasuda
  • Kouichi Morita
  • 全て表示

18
18
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.3390/ijerph18189630

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of coronavirus disease 2019 (COVID-19). Real-time RT-PCR is the most commonly used method for COVID-19 diagnosis. However, serological assays are urgently needed as complementary tools to RT-PCR. Hachim et al. 2020 and Burbelo et al. 2020 demonstrated that anti-nucleocapsid(N) SARS-CoV-2 antibodies are higher and appear earlier than the spike antibodies. Additionally, cross-reactive antibodies against N protein are more prevalent than those against spike protein. We developed a less cross-reactive immunoglobulin G (IgG) indirect ELISA by using a truncated recombinant SARS-CoV-2 N protein as assay antigen. A highly conserved region of coronaviruses N protein was deleted and the protein was prepared using an E. coli protein expression system. A total of 177 samples collected from COVID-19 suspected cases and 155 negative control sera collected during the pre-COVID-19 period were applied to evaluate the assay's performance, with the plaque reduction neutralization test and the commercial SARS-CoV-2 spike protein IgG ELISA as gold standards. The SARS-CoV-2 N truncated protein-based ELISA showed similar sensitivity (91.1% vs. 91.9%) and specificity (93.8% vs. 93.8%) between the PRNT and spike IgG ELISA, as well as also higher specificity compared to the full-length N protein (93.8% vs. 89.9%). Our ELISA can be used for the diagnosis and surveillance of COVID-19.

リンク情報
DOI
https://doi.org/10.3390/ijerph18189630
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34574555
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8469721
ID情報
  • DOI : 10.3390/ijerph18189630
  • PubMed ID : 34574555
  • PubMed Central 記事ID : PMC8469721

エクスポート
BibTeX RIS